Goldenwell Biotech notifies late 10-Q, expects May 19 filing

Goldenwell Biotech, Inc. notifies the SEC it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026.

Accepted by SEC EDGAR 05/12/2026 - 06:02 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Goldenwell Biotech, Inc. notifies the SEC it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company states it was unable, without unreasonable effort or expense, to compile the financial statements and related disclosures and expects to file on or before May 19, 2026.

The notification, signed by Hua Xie, Secretary and principal accounting officer, also notes the Annual Report on Form 10-K for the year ended March 31, 2026 has not been filed.

Insights

Corporate Governance Analyst

Late 10-Q filing indicates disclosure timing risk; company set a target date to cure the delay.

The company cites difficulty compiling required financial statements and related disclosures for the quarter ended March 31, 2026, and expects to file by May 19, 2026. This is a procedural disclosure under Rule 12b-25 rather than a determination of financial outcomes.

Key dependencies include completion of financial close and any external audit procedures. Subsequent filings will reveal whether the delay reflects timing issues or material adjustments.

Key Figures

Quarter end: March 31, 2026 Expected filing date: May 19, 2026 Contact phone: (440) 666-7999 +1 more

4 metrics

Quarter end March 31, 2026 Period for the delayed Form 10-Q

Expected filing date May 19, 2026 Registrant's stated target to file the Form 10-Q

Contact phone (440) 666-7999 Contact provided for the notification (Hua Xie)

SEC file number 000-56275 File number shown on the NT 10-Q cover table

Key Terms

Rule 12b-25, Form NT 10-Q, Quarterly Report on Form 10-Q

3 terms

Rule 12b-25 regulatory

"The Registrant has been unable, without unreasonable effort or expense, to timely compile"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form NT 10-Q regulatory

"NOTIFICATION OF LATE FILING"

A Form NT 10-Q is a notice filed with the U.S. Securities and Exchange Commission when a company cannot file its quarterly report (Form 10-Q) on time. It explains the reason for the delay and when the company expects to file the missing report; investors use it like a traffic advisory that signals a pause or delay in receiving a company’s routine, audited financial update and related disclosures.

Quarterly Report on Form 10-Q regulatory

"Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026"

A quarterly report on Form 10-Q is a standardized financial filing public companies must submit to U.S. regulators every three months, summarizing recent financial results, cash flows, balance sheet changes, operations and material risks or legal developments. Investors treat it like a company report card that shows up-to-date facts rather than marketing copy, helping them track performance, spot trends, reassess risk and make buy or sell decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Goldenwell Biotech (GWLL) file with the SEC?

Goldenwell Biotech filed a Form NT 10-Q notifying a late Quarterly Report for the period ended March 31, 2026. The filing states the company could not timely compile required financial statements and expects to file the Form 10-Q on or before May 19, 2026.

When does Goldenwell Biotech expect to file the late Form 10-Q?

The company expects to file the Quarterly Report on Form 10-Q on or before May 19, 2026. That date is presented as the registrant's estimated cure date for the late filing under Rule 12b-25.

Does the NT 10-Q state why the 10-Q is late?

Yes. Goldenwell Biotech states it was unable, without unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures for the quarter ended March 31, 2026. No further quantitative explanation is provided in the notice.

Has Goldenwell Biotech filed its Form 10-K for the fiscal year ended March 31, 2026?

No. The NT 10-Q discloses the registrant's Annual Report on Form 10-K for the fiscal year ended March 31, 2026 has not been filed. The notice does not state a separate filing date for the 10-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

		SEC FILE NUMBER
		000-56275
	NOTIFICATION OF LATE FILING	CUSIP NUMBER
		38138N104

(Check One):	☐	Form 10-K	☐	Form 20-F	☐	Form 11-K	☒	Form 10-Q
	☐	Form 10-D	☐	Form N-SAR	☐	Form N-CSR
	For Period Ended:   March 31, 2026 ☐     Transition Report on Form 10-K ☐     Transition Report on Form 20-F ☐     Transition Report on Form 11-K ☐     Transition Report on Form 10-Q ☐     Transition Report on Form N-SAR For the Transition Period Ended: ___________________

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I -- REGISTRANT INFORMATION

Full Name of Registrant:	Goldenwell Biotech, Inc.
Former Name if Applicable:	None
Address of Principal Executive Offices (Street and Number):	7316 Capilano Dr., Solon, Ohio 44139

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

		(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without  unreasonable effort or expense;
☒		(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
		(c)	The accountant's statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable.

PART III -- NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures required to be included in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026.   The Registrant expects to file the Quarterly Report on or before May 19, 2026.

PART IV --OTHER INFORMATION

(1)  Name  and  telephone  number  of  person  to  contact  in  regard  to  this notification:

Hua Xie		(440)		666-7999
Name		Area Code		Telephone Number

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☐ Yes     ☒ No

The Registrant’s Annual Report Form 10-K for the fiscal year ended March 31, 2026, has not been filed.

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ? ☐ Yes     ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

Goldenwell Biotech, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 12, 2026	By:	/s/ Hua Xie
		Name:  Hua Xie Title:  Secretary (principal accounting officer and principal financial officer)

Instruction: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).

3